GlaxoSmithKline (GSK) is dedicating $1.2bn to accelerate research and development (R&D), for over a decade, to investigate and prevent infectious diseases in lower-income countries. This research will concentrate on exploring preventions and treatments for malaria, tuberculosis, HIV, NTDs, and AMR as these diseases are responsible for 60% burden in most of the lower-income countries. The investment will enable the company to come up with next-generation vaccines and therapies for diseases such as malaria and tuberculosis. Moreover, the patients suffering from the said diseases will have access to shorter therapy treatments.
Read More from Pharmaceutical-Technology
English